• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    InMode Announces Health Canada Certification of the IgniteRF Platform with the New QuantumRF Technology

    5/20/25 9:17:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    YOKNEAM, Israel, May 20, 2025 /CNW/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, is pleased to announce Health Canada certification of IgniteRF, an advanced platform offering a comprehensive suite of minimally invasive radiofrequency solutions for the face and body.

     

    InMode Logo

     

    IgniteRF is equipped with nine proprietary technologies, including the new QuantumRF, Morpheus8 Burst and Burst Deep, BodyTite Turbo, and FaceTite Turbo handpieces. This advanced complement of technologies leverages the heritage and efficacy of clinically proven bipolar radiofrequency to address consumer demand for minimal downtime procedures that deliver natural-looking results. Unlike more surgical procedures, IgniteRF treatments do not require extensive surgery or lengthy recovery periods. Engineered with the functionality to penetrate multiple tissue depths, IgniteRF is capable of treating superficial tissue at 0.5mm to deeper tissue at 60mm, giving physicians the versatility to deliver noticeable outcomes with minimal discomfort or downtime. 

    QuantumRF is InMode's newest breakthrough technology in its renowned portfolio of radiofrequency handpieces. It is the ultimate minimally invasive technology, deploying fractionated radiofrequency (FRF) to maximal depths to heat deeper layers of the skin. QuantumRF is available in two lightweight cannulas: QuantumRF 10 for smaller, more delicate zones and QuantumRF 25 for larger areas. Certified by Health Canada for skin tightening, it delivers safe, quick, and highly efficacious procedures, enabling practices to provide consistent, unparalleled outcomes to consumers seeking a more youthful appearance.

    Moshe Mizrahy, CEO and Co-founder of InMode, commented, "Launching IgniteRF in Canada further expands our global innovation footprint, bringing our fastest, most efficacious technologies to more doctors who want to provide their patients with exceptional results."

    About InMode 

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

    Logo: https://mma.prnewswire.com/media/1064477/5298285/InMode_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/inmode-announces-health-canada-certification-of-the-igniterf-platform-with-the-new-quantumrf-technology-302460552.html

    SOURCE InMode Ltd.

    Cision View original content: http://www.newswire.ca/en/releases/archive/May2025/20/c6363.html

    Get the next $INMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    SEC Filings

    See more
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      5/19/25 7:00:11 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      4/28/25 7:00:06 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      4/3/25 7:07:38 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • InMode downgraded by BTIG Research

      BTIG Research downgraded InMode from Buy to Neutral

      4/29/25 8:06:22 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

      4/28/25 1:56:11 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BTIG Research initiated coverage on InMode with a new price target

      BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

      10/17/24 7:41:34 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

      SC 13G/A - InMode Ltd. (0001742692) (Subject)

      2/13/24 4:31:18 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

      SC 13G/A - InMode Ltd. (0001742692) (Subject)

      2/13/24 4:25:40 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by InMode Ltd.

      SC 13G - InMode Ltd. (0001742692) (Subject)

      2/6/24 9:36:39 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InMode Announces Health Canada Certification of the IgniteRF Platform with the New QuantumRF Technology

      YOKNEAM, Israel, May 20, 2025 /CNW/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, is pleased to announce Health Canada certification of IgniteRF, an advanced platform offering a comprehensive suite of minimally invasive radiofrequency solutions for the face and body.     IgniteRF is equipped with nine proprietary technologies, including the new QuantumRF, Morpheus8 Burst and Burst Deep, BodyTite Turbo, and FaceTite Turbo handpieces. This advanced complement of technologies leverages the heritage and efficacy of clinically proven bipolar radiofrequency to address consumer demand for minimal downtime procedures that deliver natural-looking results

      5/20/25 9:17:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

      Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.  The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p

      5/9/25 8:22:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode to Present at Upcoming Investor Conferences and Events

      YOKNEAM, Israel, May 7, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences: BNP 3rd Annual Aesthetics Day Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings When: Monday, May 19, fireside chat at 11:00 am ET A live webcast of the presentation can be accessed here. Barclays West Coast Bus Trip Presenters: Yair Malca, Chief Financial Officer Format: In-person investor bus tour at InMode's North American headquarters When: Thurs

      5/7/25 8:30:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Financials

    Live finance-specific insights

    See more
    • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

      Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.  The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p

      5/9/25 8:22:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease

      In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares  YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Quarterly GAAP revenues of $77.9 million, compared to $80.3 million in the first quarter of 2024.Quarterly revenues from consumables and service of $20.2 million, a decrease of 10% compared to the first quarter of 2024.GAAP operating income of $15.6 million, *non-GAAP operating income of $18.1 million.Total cash position of $512.9 million as

      4/28/25 7:00:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode to Report First Quarter 2025 Financial Results and Hold Conference Call on April 28, 2025, Expects Q1 Revenue Between $77.2M-$77.5M, Reiterates FY 2025 Revenue Guidance Between $395M-$405M

      Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025. InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

      4/14/25 7:00:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care